21 September 2023
21 September 2023
As the population ages, Alzheimer’s disease is more prevalent. Will treatment ever be effective enough or will prevention be key?
The immune response demonstrated by vididencel was similar for both acute myeloid leukaemia and ovarian cancer.
Long-term dosing with REL-1017 was well-tolerated with low rates of adverse events.
RGLS8429 was demonstrated to be well tolerated in trial participants without any safety findings reported.
Fresh Tracks is planning to seek approval for liquidation and dissolution from stakeholders pending a better offer.
The first patient is anticipated to receive the first dose of the vaccine later this year.
Initial data from the study is anticipated in the second half of next year.
Under the deal, FB849 plus Keytruda will be evaluated in a Phase I/II clinical trial for treating advanced solid tumour patients.
The Excellence Awards celebrate the greatest achievements and innovations in the industry, and the people and companies that are driving change.
The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.
Give your business an edge with our leading industry insights.
